HC Wainwright & Co. Downgrades HeartBeam to Neutral
HC Wainwright & Co. analyst Yi Chen downgrades HeartBeam (NASDAQ:BEAT) from Buy to Neutral.
Stocks · News reference
HeartBeam Reports Q2 2026 Results: Full Earnings Call Transcript
HeartBeam (NASDAQ:BEAT) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts and financial
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HeartBeam Enters ATM Equity Offering Agreement To Sell Up To $25M Of Common Stock Through Titan Partners Securities
On August 14, 2026, HeartBeam, Inc. (the "Company"), entered into an At-The-Market Equity Offering Sales Agreement (the "Sales Agreement") with Titan Partners Securities LLC, as sales agent, pursuant to
Heartbeam shares are trading lower after the company reported worse-than-expected Q2 EPS results.
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers MDxHealth (NASDAQ:MDXH) stock moved upwards by 120.8% to $1.02 during Friday's regular session. The company's market cap stands at $23.7 million. The company's, Q2 earnings came out yesterday.